Dr. Reddy’s Laboratories has been granted permission by the Delhi High Court to supply its remaining stock of Olymviq, a generic version of the diabetes drug semaglutide, to government hospitals. This decision comes after a 30-day window during which the company was restricted from distributing the drug due to a patent dispute with Novo Nordisk, the maker of Ozempic.
The court’s ruling ensures that patients dependent on semaglutide for managing their diabetes will continue to have access to the medication through public healthcare facilities. Dr. Reddy’s will be able to clear its existing inventory, preventing potential wastage of the drug.
This development highlights the ongoing legal battles surrounding generic versions of blockbuster drugs like Ozempic, as pharmaceutical companies seek to protect their intellectual property while also addressing the need for affordable medications. The availability of generic alternatives can significantly impact the cost of treatment for chronic conditions like diabetes, making them more accessible to a wider population.
The decision by the Delhi High Court balances the interests of both innovator companies and the public health system, allowing for the continued supply of a crucial medication while respecting patent rights. It remains to be seen how this ruling will influence future disputes involving generic drugs and intellectual property in the pharmaceutical industry.
About the Author
